{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:51:31Z","timestamp":1773424291439,"version":"3.50.1"},"reference-count":56,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Several targeted treatments, such as venetoclax\u00a0+ obinutuzumab (VenO) and ibrutinib, have\u00a0been developed to treat patients with treatment-naive chronic lymphocytic leukemia (CLL) and have been shown to improve progression-free survival compared with chlorambucil\u00a0+ obinutuzumab (ClbO). However, novel targeted agents are associated with a significant cost investment. The objective of this study was to investigate the cost-effectiveness of VenO compared with ClbO and ibrutinib in treatment-naive CLL without del17p\/TP53 mutation in Denmark. We used a decision-analytic modeling approach to simulate hypothetical cohorts of patients with CLL from the initiation of first-line treatment to death, including the full treatment pathway and second-line therapy. VenO, ClbO, or ibrutinib was included as first-line therapy followed by either Ven\u00a0+ rituximab or ibrutinib. Model outcomes were expected quality-adjusted life years (QALYs), life years (LYs), and cost per patient, which were used to calculate incremental cost-effectiveness ratios (ICERs) with a willingness to pay from \u20ac23\u2009600 to \u20ac35\u2009600 per QALY. Compared with ClbO, VenO was associated with a QALY gain of 1.30 (1.42 LYs) over a lifetime. The incremental cost was \u20ac12\u2009360, resulting in an ICER of \u20ac9491 per QALY gained, indicating that VenO is cost-effective. Compared with VenO, ibrutinib was associated with a QALY gain of 0.82 (1.74 LYs) but at a substantially increased incremental cost of \u20ac247\u2009488 over a lifetime horizon. The ICER was \u20ac302\u2009156 per QALY, indicating that ibrutinib in first-line treatment would not be considered cost-effective in Danish health care, compared with VenO. Future analyses in fit patients with CLL are needed to determine the cost-effectiveness of VenO.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010108","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T16:34:19Z","timestamp":1684168459000},"page":"4186-4196","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without <i>TP53<\/i> aberrations"],"prefix":"10.1182","volume":"7","author":[{"given":"Matilde","family":"Slot","sequence":"first","affiliation":[{"name":"1Nordic Institute of Health Economics, Aarhus, Denmark"},{"name":"2Department of Public Health, Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten Utoft","family":"Niemann","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-5566","authenticated-orcid":false,"given":"Lars Holger","family":"Ehlers","sequence":"additional","affiliation":[{"name":"1Nordic Institute of Health Economics, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-772X","authenticated-orcid":false,"given":"Emelie Curovic","family":"Rotbain","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"4Hematology Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"issue":"suppl 5","key":"2023080717253017600_bib1","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"2023080717253017600_bib2","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"2023080717253017600_bib3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10198-021-01398-7","article-title":"Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed\/refractory chronic lymphocytic leukemia in Switzerland.","volume":"23","author":"Barbier","year":"2022","journal-title":"Eur J Health Econ"},{"issue":"15","key":"2023080717253017600_bib4","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/bloodadvances.2017015461","article-title":"Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p","volume":"2","author":"Barnes","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2023080717253017600_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023080717253017600_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"2023080717253017600_bib7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","article-title":"NCCN Guidelines\u00ae Insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, Version 3.2022: featured updates to the NCCN Guidelines","volume":"20","author":"Wierda","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"2023080717253017600_bib8","author":"Dansk Lymfomgruppe, Danske Multidisciplin\u00e6re Cancergrupper (DMCG)","year":"2022"},{"key":"2023080717253017600_bib9","author":"Al-Sawaf","year":"2022"},{"issue":"9","key":"2023080717253017600_bib10","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematol"},{"issue":"1","key":"2023080717253017600_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"2023080717253017600_bib12","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"issue":"26","key":"2023080717253017600_bib13","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2023080717253017600_bib14","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"key":"2023080717253017600_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/EDBK_238735","article-title":"Tailored treatment strategies for chronic lymphocytic leukemia in a rapidly changing Era","volume":"39","author":"Brander","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"2023080717253017600_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"2023080717253017600_bib17","author":"Medicinr\u00e5det","year":"2020"},{"key":"2023080717253017600_bib18","author":"Wei","year":"2018"},{"issue":"4","key":"2023080717253017600_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and markov decision-analytic modeling","volume":"37","author":"Williams","year":"2017","journal-title":"Med Decis Making"},{"key":"2023080717253017600_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"34","key":"2023080717253017600_bib21","first-page":"4042","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J\u00a0Clin Orthod"},{"issue":"5","key":"2023080717253017600_bib22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/ejh.13499","article-title":"Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"105","author":"Aarup","year":"2020","journal-title":"Eur J Haematol"},{"issue":"4","key":"2023080717253017600_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"2023080717253017600_bib24","doi-asserted-by":"crossref","first-page":"e820","DOI":"10.1016\/j.clml.2021.06.010","article-title":"Comparative efficacy of first-line treatments of chronic lymphocytic leukemia: network meta-analyses of survival curves","volume":"21","author":"Alrawashdh","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2023080717253017600_bib25","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"issue":"25","key":"2023080717253017600_bib26","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2023080717253017600_bib27","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"2023080717253017600_bib28","unstructured":"Danish Ministry of Finance\n          . Dokumentationsnotat - den samfunds\u00f8konomiske diskonteringsrente. 2021. https:\/\/fm.dk\/media\/18371\/dokumentationsnotat-for-den-samfundsoekonomiske-diskonteringsrente_7-januar-2021.pdf."},{"key":"2023080717253017600_bib29","unstructured":"Forside. https:\/\/www.medicinpriser.dk\/?lng=2."},{"issue":"1","key":"2023080717253017600_bib30","doi-asserted-by":"crossref","first-page":"e8933","DOI":"10.1371\/journal.pone.0008933","article-title":"The average body surface area of adult cancer patients in the UK: a multicentre retrospective study","volume":"5","author":"Sacco","year":"2010","journal-title":"PLoS One"},{"issue":"11","key":"2023080717253017600_bib31","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.18553\/jmcp.2021.27.11.1532","article-title":"Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States","volume":"27","author":"Chatterjee","year":"2021","journal-title":"JMCP"},{"key":"2023080717253017600_bib32","unstructured":"Interaktiv DRG. https:\/\/interaktivdrg.sundhedsdata.dk\/#\/."},{"key":"2023080717253017600_bib33","author":"Vestergaard","year":"2023"},{"key":"2023080717253017600_bib34","author":"Medicinr\u00e5det","year":"2020"},{"issue":"12","key":"2023080717253017600_bib35","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2023080717253017600_bib36","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2023080717253017600_bib37","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-4890","article-title":"Clinical outcomes in patients with multi-hit TP53 chronic lymphocytic leukemia treated with ibrutinib","volume":"27","author":"Brieghel","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2023080717253017600_bib38","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2023080717253017600_bib39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"2023080717253017600_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2021-146161","article-title":"A\u00a0randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR\/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: first co-primary endpoint analysis of the international intergroup GAIA (CLL13) Trial","volume":"138","author":"Eichhorst","year":"2021","journal-title":"Blood"},{"key":"2023080717253017600_bib41","unstructured":"German CLL Study Group\n          . A\u00a0phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR\/BR) versus rituximab plus venetoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit patients with previously untreated chronic lymphocytic leukemia (CLL) without Del(17p) or TP53 mutation. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02950051."},{"issue":"25","key":"2023080717253017600_bib42","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2023080717253017600_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s41669-022-00375-x","article-title":"A\u00a0probabilistic cost-effectiveness analysis of venetoclax and obinutuzumab as a first-line therapy in chronic lymphocytic leukemia in Canada","volume":"7","author":"Chatterjee","year":"2023","journal-title":"Pharmacoecon Open"},{"issue":"4","key":"2023080717253017600_bib44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report","volume":"12","author":"Drummond","year":"2009","journal-title":"Value Health"},{"issue":"1","key":"2023080717253017600_bib45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12874-022-01536-6","article-title":"Assessing transferability in systematic reviews of health economic evaluations \u2013 a review of methodological guidance","volume":"22","author":"Weise","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"2023080717253017600_bib46","first-page":"72","author":"Woods","year":"2017"},{"key":"2023080717253017600_bib47","unstructured":"European Medicines Agency\n          . Summary of opinion - post authorisation. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-imbruvica-ii-70_en.pdf."},{"key":"2023080717253017600_bib48","unstructured":"Final appraisal document - venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. 2020. https:\/\/www.nice.org.uk\/guidance\/ta663\/documents\/final-appraisal-determination-document."},{"issue":"5","key":"2023080717253017600_bib49","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3109\/10428194.2014.961012","article-title":"Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival","volume":"56","author":"Kosmas","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023080717253017600_bib50","doi-asserted-by":"crossref","first-page":"e000419","DOI":"10.1136\/openhrt-2016-000419","article-title":"Health utility indexes in patients with acute coronary syndromes","volume":"3","author":"Gencer","year":"2016","journal-title":"Open Heart"},{"key":"2023080717253017600_bib51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-8-50","article-title":"Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study","volume":"8","author":"Beusterien","year":"2010","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"2023080717253017600_bib52","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0272989X11401031","article-title":"Catalogue of EQ-5D Scores for the United Kingdom","volume":"31","author":"Sullivan","year":"2011","journal-title":"Med Decis Making"},{"issue":"1","key":"2023080717253017600_bib53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12955-018-1013-9","article-title":"Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States","volume":"16","author":"Stein","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"2023080717253017600_bib54","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10198-012-0419-2","article-title":"Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia","volume":"14","author":"Tolley","year":"2013","journal-title":"Eur J Health Econ"},{"key":"2023080717253017600_bib55","volume-title":"23rd congress of the European Haematology Association","author":"Wehler","year":"2018"},{"issue":"5","key":"2023080717253017600_bib56","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non-small cell lung cancer: an international study","volume":"13","author":"Nafees","year":"2017","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/4186\/2069880\/blooda_adv-2023-010108-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/4186\/2069880\/blooda_adv-2023-010108-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T17:25:55Z","timestamp":1691429155000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/15\/4186\/495844\/Cost-effectiveness-of-targeted-treatment-vs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":56,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010108","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}